ReviewTranslational lung cancer research2016
Targeted drugs in small-cell lung cancer.
Review in Translational lung cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 40 citations in OpenAlex.
- The potential applications of peptide-loading complex in cancer treatment.Frontiers in immunology · 2025Review
- Mapping the evolution and frontiers ofTranslational lung cancer research · 2024Review
- Recent advances on high-efficiency of microRNAs in different types of lung cancer: a comprehensive review.Cancer cell international · 2023Review
- Review
- The role of alternative splicing in lung cancer.Cancer chemotherapy and pharmacology · 2023Review
- Evaluating Histological Subtypes Classification of Primary Lung Cancers on Unenhanced Computed Tomography Based on Random Forest Model.Journal of healthcare engineering · 2023Article
- Combined small cell lung cancer: current progress and unmet needs.American journal of cancer research · 2023Review
- Changes of protein expression during tumorosphere formation of small cell lung cancer circulating tumor cells.Oncology research · 2023Article
- Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer.Science advances · 2022Article
- Angiomotin-p130 inhibits vasculogenic mimicry formation of small cell lung cancer independently of Smad2/3 signal pathway.Journal of bioenergetics and biomembranes · 2021Article
- A deep learning model for the classification of indeterminate lung carcinoma in biopsy whole slide images.Scientific reports · 2021Article
- Comprehensive genomic profiling of combined small cell lung cancer.Translational lung cancer research · 2021Article
- Combination therapy: Future directions of immunotherapy in small cell lung cancer.Translational oncology · 2021Review
- A noteworthy treatment of metastatic small-cell lung cancer with afatinib, followed by subsequent development of rare metastatic lesions in the ascending and sigmoid colon.Cancer reports (Hoboken, N.J.) · 2020Article
- IL-7-Mediated IL-7R-JAK3/STAT5 signalling pathway contributes to chemotherapeutic sensitivity in non-small-cell lung cancer.Cell proliferation · 2019Article
- Ex vivo culture of cells derived from circulating tumour cell xenograft to support small cell lung cancer research and experimental therapeutics.British journal of pharmacology · 2019Article
- Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer.Translational lung cancer research · 2018Article
- The 180 splice variant of NCAM-containing exon 18-is specifically expressed in small cell lung cancer cells.Translational lung cancer research · 2018Article
- Advanced small cell lung cancer (SCLC): new challenges and new expectations.Annals of translational medicine · 2018Review
- Clinical Significance of Gli-1 And Caveolin-1 Expression in the Human Small Cell Lung CancerAsian Pacific journal of cancer prevention : APJCP · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In contrast to non-small-cell lung cancer (NSCLC), few advances have been made in systemic treatment of small-cell lung cancer (SCLC) in recent years. Most patients are diagnosed with extensive stage disease and are commonly treated with platinum-based chemotherapy which, although attaining high initial objective responses, has a limited impact on survival. Due to the dismal prognosis of SCLC, novel and more effective treatment strategies are urgently needed. A deeper characterization of the genomic landscape of SCLC has led to the development of rational and promising targeted agents. However, despite a large number of clinical trials, results have been disappointing and there are still no approved targeted drugs for SCLC. Recent comprehensive genomic studies suggest SCLC is a heterogeneous disease, characterized by genomic alterations targeting a broad variety of genes, including those involved in transcription regulation and chromatin modification which seem to be a hallmark of this specific lung cancer subtype. Current research efforts are focusing on further understanding of the cellular and molecular abnormalities underlying SCLC development, progression and resistance to chemotherapy. Unraveling the genomic complexity of SCLC could be the key to optimize existing treatments, including chemotherapy and radiotherapy, and for identifying those patients most likely to benefit from selected targeted therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.